PharmExec reports the recommendation doesnt add anything to the approved compounding list on its own
For example, a 2011 study in rats found that the peptide successfully healed various lesions and promoted healthy weight gain in models of short-bowel syndrome.14 Additionally, as researchers note in the aforementioned 2016 review on BPC-157 and the gut-brain axis, BPC 157 was successful in the therapy of GI tract, periodontitis, liver and pancreas lesions, and in the healing of various tissues and wounds. Its also written in the review that the peptide acts as a mediator of Roberts cytoprotection, defined as the counteraction of the lesions arising from direct detrimental contact with a noxious agent.7 15 Insider Tip: Though there has been some small-scale positive human research on BPC-157, most of the peptides potential uses are based on the outcomes of animal or cell studies
MDM2 induces pro-inflammatory and glycolytic responses in M1 macrophages by integrating iNOS-nitric oxide and HIF-1 pathways in mice
This metabolic phenotype was similar to that of obese human type 2 diabetic subjects 18
[Expression of glutathione S-transferase isoenzymes in research subjects gliomas] [PMID: 16124382] Laboratory literature summary: [Expression of glutathione S-transferase isoenzymes in research subjects gliomas]
